LATEST NEWS
Novavax and Catalent Announce Closing of Strategic Partnership
GAITHERSBURG, MD, July 31, 2019: Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Catalent Biologics’ Paragon Gene Therapy unit, the leading viral vector development and...
Catalent Biologics Announces Agreement to Provide Additional Production of Approved Gene Therapy Treatment for Spinal Muscular Atrophy
SOMERSET, NJ - July 16, 2019 — Catalent Biologics today announced a long-term strategic agreement for the development and manufacturing of Zolgensma® (onasemnogene abeparvovec-xioi), an AveXis gene therapy treatment for spinal muscular atrophy (SMA). Through...
Novavax and Catalent Biologics Enter Strategic Partnership: Allowing Catalent Biologics to Expand Gene Therapy Footprint with Acquisition of Novavax’ Manufacturing Assets and Capabilities
GAITHERSBURG, MD, June 27, 2019 (GLOBE NEWSWIRE): Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Catalent Biologics’ Paragon Gene Therapy unit, the leading viral vector...
MEDIA & PRESS CONTACT
Colleen Floreck, Senior Director, Marketing and Communications
+1 443-262-3246 | cfloreck@paragonbioservices.com
JOIN THE CONVERSATION
Follow us on social media:
EVENTS
Come meet us!
BioProcess International
September 9 – 12, 2019
Booth 202
Boston, MA
Cell & Gene Meeting on the Mesa
October 2 – 4, 2019
Carlsbad, CA
ESGCT
October 22 – 25, 2019
Barcelona, Spain
Paragon Bioservices will be attending and or be exhibiting at the following events.
We would be delighted to meet you in person during the show. Contact us to schedule a time to discuss your needs!